Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Author(s): Pier Luigi Zinzani ^1,2;Catherine Thieblemont ³;Vladimir Melnichenko ⁴;Krimo Bouabdallah ⁵;Jan Walewski ⁶;Alejandro Majlis ⁷;Laura Fogliatto ⁸;A. Martin Garcia-Sancho ⁹;Beth Christian ¹⁰;Zafer Gulbas ¹¹;Muhit Özcan ¹²;Guilherme Fleury Perini ¹³;Herve Ghesquieres ¹⁴;Margaret A. Shipp ¹⁵;Seth Thompson ¹⁶;Samhita Chakraborty ¹⁶;Patricia Marinello ¹⁶;Philippe Armand ¹⁵;

Source: Blood (2023) 142 (2): 141–145.

Dr. Maen Hussein's Thoughts

Pembrolizumab in lymphoma, this is not a common one, usually in young females, could be hard to treat.

ABSTRACT

Previous analyses of the phase 2 KEYNOTE-170 (NCT02576990) study demonstrated effective antitumor activity and acceptable safety of pembrolizumab 200 mg given every 3 weeks for up to 35 cycles (∼2 years) in patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) whose disease progressed after or who were ineligible for autologous stem cell transplantation. The end points included objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR) according to the investigator per 2007 Response Criteria; overall survival (OS); and safety. In this final analysis, median duration of follow-up was 48.7 months (range, 41.2-56.2). The ORR was 41.5% (complete response, 20.8%; partial response, 20.8%). The median DOR was not reached; no patients who achieved a complete response progressed at the data cutoff. The median PFS was 4.3 months; the 4-year PFS rate was 33.0%. The median OS was 22.3 months; the 4-year OS rate was 45.3%. At the data cutoff, 30 patients (56.6%) had any-grade treatment-related adverse events (AEs); the most common were neutropenia, asthenia, and hypothyroidism. Grade 3/4 treatment-related AEs occurred in 22.6% of the patients; no grade 5 AEs occurred. After 4 years of follow-up, pembrolizumab continued to provide durable responses, with promising trends for long-term survival and acceptable safety in R/R PMBCL.

Author Affiliations

¹IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli,” Bologna, Italy;²Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy;³Department of Hemato-Oncology, Hôpital Saint-Louis APHP, Paris, France;⁴Department of Medical Oncology, Pirogov National Medical Surgical Center, Moscow, Russia;⁵Department of Hematology and Cellular Therapy, University Hospital, Bordeaux, France;⁶Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, European Reference Network, Warsaw, Poland;⁷Department of Hemato-Oncology, Clinica Alemana de Santiago, Santiago, Chile;⁸Department of Clinical Hematology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil;⁹Department of Hematology, Hospital Universitario de Salamanca, Institute of Biomedical Research of Salamanca, Centro de Investigación Biomédica en Red Cáncer, Salamanca, Spain;¹⁰Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH;¹¹Department of Hematologic Oncology, Anadolu Medical Center, Gebze, Turkey;¹²Department of Hematology and Bone Marrow Transplantation Unit, Ankara University School of Medicine, Ankara, Turkey;¹³Department of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil;¹⁴Department of Clinical Hematology, Lyon-Sud Hospital Center, Lyon, France;¹⁵Department of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA;¹⁶Department of Medical Oncology, Merck & Co, Inc, Rahway, NJ;

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Mosunetuzumab has an impressive response rate and durability of response in heavily pre-treated patients with B-cell NHL. This was presented at our webinar on August 7, 2024 by the cellular therapy team, slides are available upon request. We have this drug available at select sites within our practice so please contact us if you have a patient in mind.

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

For transplant-eligible patients with Mantle Cell Lymphoma, Obinutuzumab showed superior efficacy compared to Rituximab. These patients are uncommon, but the results of this study show that in this context O seems to beat R in every aspect, including a 5-yr PFS of 82.8 vs 66.6%, which is striking. I would consider this option for the appropriate patient.

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

This combination had impressive results but led to a high rate of ventricular arrythmias (9%), hence the combination is not recommended. Another study with the combination and rituximab was also suspended, the etiology of the higher rate of Vent arrhythmias is not known. This combination in another lymphoid malignancies did not lead to that rate of toxicity.

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

This gives more credence to the idea of avoiding bendamustine before CAR T therapy. Patients exposed to bendamustine had about a 20% lower overall response rate (ORR), 50% shorter progression-free survival (PFS) and >50% shorter overall survival (OS) compared to those who were bendamustine naive. Although other factors may also play a role here, these seem to be significant differences and should make it clear that one should not use this drug before pursuing CAR T therapy.

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Good review of high-risk patients, showing that prophylactic high dose MTX did not have lower risk of CNS disease.

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Dr. Maen Hussein's Thoughts

ABSTRACT

Author Affiliations

Leave a Comment Cancel Reply

Related Articles

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

Menu

About This Site